Our R&D portfolio for cryptococcal meningitis

Cryptococcal meningitis

Our R&D portfolio for cryptococcal meningitis

What we have achieved

We have joined a broad network of partner organizations, the Cryptococcal Meningitis Action Group, advocating for better access to life-saving treatment combinations for people with cryptococcal meningitis. Ending cryptococcal meningitis deaths by 2030 is its overarching goal.

Loading…

What we are doing for people living with cryptococcal meningitis

Our aim is to facilitate the scale-up of key medicines in selected, trailblazer African low- and middle-income countries through a comprehensive action plan. We are also working to develop a better formulation of the existing medicines.

Loading…

Translational research

Sustained release 5FC

An improved formulation of a key medicine. We are developing a formulation of an HIV-related cryptococcal meningitis medicine that can be taken orally or through a nasogastric tube. The medicine only needs to be taken twice a day rather than four times a day.

Registration & access

Immediate-release flucytosine & liposomal amphotericin B access

Address the supply and demand barriers limiting access to immediate-release flucytosine and liposomal amphotericin B for cryptococcal meningitis in low- and middle-income countries.

Building capacity, uniting expertise

Initiatives to utilize and strengthen research capacities in low- and middle-income countries and support networks of excellence to sustain public-interest R&D are central to our virtual R&D model.

Partnering for patients

Collaboration is an essential part of how we work. We have forged a diverse range of alliances and research collaborations with over 200 partners in more than 40 countries.

Making medical history for neglected patients

We develop urgently needed treatments for neglected patients and ensure they’re affordable, available, and adapted to the communities who need them

Doctor diagnosing a man in a village with his hands on the man's neck

Sleeping sickness

Transmitted by the bite of a tsetse fly and causes severe neurological disorders

We delivered a revolutionary new drug to replace toxic treatments, and have ongoing trials to eliminate this disease

Young boy sitting on a hospital bed being examined by a nurse

Chagas disease

Causes heart and vital organ damage, after people are bitten by blood-sucking bugs

We delivered the first-ever treatment for children; now we’re searching for new drug candidates and working to boost access to care

Cutaneous leishmaniasis

Leaves disfiguring, life-long scars that lead to severe social stigma

We’re working to develop safer, shorter treatments for this disabling disease

Hepatitis C

Millions are left without treatment even though effective drugs exist

We’ve delivered a treatment as simple, safe, and effective as the best drugs available today – at a fraction of the cost

Visceral leishmaniasis

Is one of the world’s biggest parasitic killers, spread by the bites of sandflies

We’re working to develop a new generation of treatments to replace drugs that are painful, ineffective, and cause side effects

COVID-19

Devasting and deadly to many, there’s too little research to help the most vulnerable

We’re accelerating research by coordinating clinical trials in low-resource settings and bringing together partners

Father walking in rural village with a cane and holding his son's hand

Filaria: river blindness

Lead to unbearable itching, disfiguring skin lesions, and even blindness

We’re working to develop a safe, effective, and affordable drug for the prevention and treatment of this debilitating disease